Bronwen Bastone - 08 Aug 2023 Form 4 Insider Report for Enfusion, Inc. (ENFN)

Role
Chief People Officer
Signature
/s/ Matthew Campobasso, as Attorney-in-Fact
Issuer symbol
ENFN
Transactions as of
08 Aug 2023
Transactions value $
-$458
Form type
4
Filing time
10 Aug 2023, 18:49:06 UTC
Previous filing
20 Jun 2023
Next filing
11 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENFN Class A Common Stock Award $0 +153 +0.1% $0 156,657 08 Aug 2023 Direct F1
transaction ENFN Class A Common Stock Sale -$457 -55 -0.04% $8.32 156,602 09 Aug 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of fully vested shares issued under the Enfusion, Inc. 2021 Stock Option and Incentive Plan in connection with the previously disclosed pre-IPO termination of the Enfusion Ltd. LLC Change in Control Bonus Plan (the "Shares").
F2 Consists of shares required by the Issuer to be sold by the Reporting Person to cover tax withholding obligations in connection with the issuance of the Shares, and does not represent discretionary trades by the Reporting Person.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.48. Full information regarding the number of shares sold at each separate price will be furnished to the SEC staff upon request.